• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Novel 5-(subst. phenyl)-oxazolidinones and their sulphur analogs of the general formula I <IMAGE> in which the substituents are defined in Claim 1, are obtained by reacting 2-amino-1(3,4-disubst. phenyl)-ethanols with a carbonic acid derivative or a thiocarbonic acid derivative in an inert solvent while heating in the presence of a basic catalyst. The novel compounds of the general formula I possess valuable pharmacological properties. They exhibit antidopaminergic, antinociceptive and anticonvulsive effects and have a depressant action on the central nervous system and thus have a certain similarity to neuroleptic agents such as chlorpromazine or haloperidol. In addition, the novel compounds possess strong phosphodiesterase-inhibiting properties and thus affect the metabolism of cyclic nucleotides. The compounds are also suitable for treating hyperproliferative diseases and diseases associated with uncontrolled cell growth.
    公开号:SU888821A3
    申请号:SU772546252
    申请日:1977-11-28
    公开日:1981-12-07
    发明作者:Хут Андреас；Шмихен Ральф；Кер Вольфганг；Пашельке Герт；Вахтель Хельмут
    申请人:Шеринг Аг (Инофирма)；
    IPC主号:
    专利说明:

    where R is phenyl, substituted phenyl, in that the compound of the general formula KrJ-JH2-0-C-NH2,; About R where R ,, has the above values is subjected to cisilisation in the presence of trifluoroacetic acid or p-toluene sulfonic acid 1. The aim of the invention is to obtain new oxazolidinone derivatives, expanding the arsenal of means of influence on a living organism. This goal is achieved by the fact that in the process for the preparation of compounds of the general formula (D), 2-amino-1- (3,4-disaJ) Phenyl-ethanol, a common formula of the general formula, is HNRj where - have the aforementioned values, are reacted with a derivative of a carbon or thiogonic acid of the general formula (I) where at X is oxygen, Rj means independently ORg, chloro) or imidazolyl, RQ is alkyl, or at X is sulfur, Rj, and R, together the same means sulfur, in an inert solvent when heated in the presence of a basic catalyst. Example 1. 5- (3-Benzyloxy-4-methoxiphenyl) -2-oxazolidinone. 318.6 mmol C-Benzyloxy-4-methoxybenzaldehyde is dissolved in 1200 MP ether. To this solution is added a solution of 558 mmol of potassium cyanogen in 300 ml of water at room temperature. After cooling, 237 mmol of 2N sulfuric acid is added dropwise to the well stirred mixture, and the reaction mixture is stirred for 12 hours at room temperature. After separating the aqueous phase, the ether is washed several times with 50 ml of a half-brine sodium chloride solution and dried thoroughly over calcium chloride. After filtering off the nitrate and subsequent washing twice with 100 ml of ether, the combined organic phases, which contain crude 2- (3-benzyloxy-4-methoxyphenyl) -2-hydroxyacetonitrile, are used in the next step. In a similar manner, 2- (3-dimethoxyphenyl) -2-hydroxyacetonitrile and 3- (3-cyclopentane-4-methoxyphenyl) -2-hydroxy-4-methoxyphenyl) -2-hydroxy-tetonyl-rhyl are obtained from 3,4-dimethoxybenzaphis aldehyde. 1.3 mmol of lithium aluminum hydride is suspended in portions in 1 liter of absolute ether, and with cooling and good stirring, the ether solution of 2- (3-benzyloxy-4-methoxyphenyl) -2-oxyacetonitrile is added dropwise with only a slight reflux. After stirring at room temperature overnight while cooling, 400 ml of ethyl acetate are added dropwise and later 600 ml of water. Then a precipitate is separated by suction and further washed twice with 200 ml of a mixture of ethanol and water (1: 1). The combined filters are concentrated strongly and dissolved with 300 ml of half-concentrated hydrochloric acid. This solution is extracted twice with 200 ml of ethyl acetate. The acetic ester phases are discarded, and the hydrochloric acid solution is cooled and alkalized with potassium hydroxide solution, the precipitated aluminum salt is sucked off and shaken with ether three times, 400 ml each time. The combined organic phases are dried, after filtration, concentrated and recrystallized from ethyl acetate. The yield of 2-amino-1- (3-benzyloxy-4-methoxyphenyl) -ethanol is 20%, T-. 101102с. Similarly, from 2- (3,4-dimethoxyphenyl) -2-hydroxy-acetonitrile in 49% yield, 2-amino-1- {3,4-dimethoxyphenyl) -ethanol (T G7d. 80-81 ° C, benzene) and from 2- (3-cyclo-pentoxy-4-methoxyphenyl) -2-hydroxy-adonitrile in 70% yield, 2-amino-1- (3-cyclopentyl-4-methoxyphenyl) -ethanol (oil) is obtained. 2-AMINO-1- (3-benzyloxy-4-methoxyphenyl) -ethanol is prepared as follows. 50 mmol of 3-benzyloxy-4-methoxybenzaldehyde and 55 mmol of trimethylallyl cyanide and 0, mmol of anhydrous zinc iodide are heated for 4 hours at 90 ° C in a nitrogen atmosphere and in the absence of moisture. It is then dissolved in 15 ml of absolute tetrahydrofuran and this solution is added dropwise to a suspension of 60 mmol of lithium aluminum hydride and 35 ml of tetrahydrofuran. After heating for 1 hour at 60 ° C, it is treated as described, NO. In Example 1. After recrystallization from ethyl acetate, 2-amino-1- (3-benzyloxy-4-methoxyphenyl) ethanol is isolated with T 100-102c and a yield of 30%. 36 mmol of 2-amino-1- (3-benzyloxy-4-methoxyphenyl) ethanol together with 50 mmol of sodium methoxide and 91.4 mmol of diethyl carbonate are suspended in 120 ml of absolute toluene, heated for 2 hours at a bath temperature of 110 ° C and in the absence of moisture, and methanol
    and ethanol is distilled. The toluene is then distilled off on an oil vacuum pump. The residue is dissolved in 150 ml of chloroform and dispersed in 100 ml of water. The aqueous phase is extracted twice with 150 ml of chloroform, the combined chloroform extracts are washed with 100 ml of water, dried, filtered, end triturated and recrystallized.
    iT Acetic Ether. 5- (3-benoyloxy-4-methoxyphenyl) -2-oxazolidinone is obtained with m.p. 132-133 ° C (yield 91%).
    Example 2. Analogously to Example 1, the oxazolidinones listed in the following table are obtained from the corresponding amino alcohols.

    -n
    -n
    -CH3 Example 3. 88.3 mmol 2-amino-1- (3-benzyloxy-4-methoxyphenyl) -. α-ethanol is dissolved in 200 ml of absolute tetrahydrofuran and mixed with 98.6 mmol of carbonyldiimidazole in the absence of moisture. The clear solution is stirred overnight at room temperature. After distilling off the tetrahydrofuran, the precipitate is dissolved in 300 ml of ethyl acetate, shaken. They are twice from 1N. hydrochloric acid is then washed with a saturated solution of sodium chloride until neutral, dried, filtered and concentrated. After recrystallization from ethyl acetate, 5- (3-benzyloxy-4-methoxyphenyl; -2-oxazolidinone is obtained, yield 66%, mp: 83-91 ° C. Example 4. 5- (3,4-Dimethoxyphenyl) -2- oxazolidinethion. 45 mmol of 2-amino-1- (3,4-dimethoxy phenyl) ethanol is dissolved in 65 ml of absolute dimethyl sulfoxide, successively mixed with 1. 8 g of powdered potassium hydroxide and 1.4 ml of carbon disulfide at. Then the reaction the mixture is stirred for 2.5 hours in the absence of moisture. After the dimethyl sulfoxide is removed by vacuum, the residue is mixed with 100 ml of water and extracted three times with 100 ml of chloroform. The dried chloroform phases are dried over anhydrous magnesium sulphate, filtered and concentrated. The residue is chromatographed, after 125 g of silica gel with a mixture of chloroform and methanol (96-4). After recrystallization of the corresponding fraction from methanol, 5- (3, -dimethoxyphenyl) -2-oxazolidine thion is obtained. The yield is 9%, Tt, 177 - 178 ° С and 6% 5- (3,4-dimethoxyphenyl) -2-thiazolidinone. The yield is 6%, 167169 ° С.
    111-112.5 Acetic ether / ether Example 5. 100 mmol of 2-amino-1- (3-dimethoxyphenyl) ethanol is dissolved in 100 ml of chloroform. After cooling to 0 ° C, a solution of 100 mmol of phosgene in 100 ml is added dropwise. chloroform so slowly that the internal temperature does not exceed. After stirring for 1 hour at 5–10 ° C, 200 mmol of pyridine in 100 ml of chloroform are added dropwise and stirred for 3 hours. After the organic phase is washed with a half-saturated sodium chloride solution, it is evaporated and recrystallized from methanol. 5- (3,4-dimethoxyphenyl) 2-oxazolidinone is obtained. Yield 75%, T p 114117 ° C. Example 6. 5- (3,4-Dimethoxyphenyl) -2-oxazolidinone. 5 mmol of 2-amino-1- (3,4-dimethoxyphenyl) ethanol is dissolved in 5 ml of 2N sodium hydroxide solution. The cooled to the solution is mixed dropwise with 10 mmol of methyl chloroformate, then it is stirred for 30 minutes at 0 ° C. The crystals formed are filtered off with suction, washed with water and dried. 2- (3,4-dimethoxyphenyl) -2-hydroxyethylcarbamic acid ethyl ester is obtained. Yield 86%, 90-92 ° C. 3 mmol of 2- (3,4-dimethoxyphenyl) 2-hydroxyethylcarbamic acid ethyl ester is suspended together with 4 mmol of sodium methylate in 12 ml of toluene and heated at the bath temperature for 2 hours in the absence of moisture. In this case, the mathenol and ethanol are distilled. Toluene is then removed in vacuo, the residue is dissolved in 50 ml of chloroform and dispersed in 10 ml of water. After drying, filtering and concentrating the organic phase, the residue is recrystallized from methanol. 5- (3,4-dimethoxyphenyl) -2-oxazolidinone is obtained. Output 80%, TPD. 114-117 ° C.
    Example 7. 3-Acetyl-5- (3,4-dimethox and phenyl) -2-oxazolidinone.
    8.9 mmol of 5- (3,4-dimethoxyphenyl) -2-oxazolidinone is mixed with 10 ml of acetic anhydride and 5 ml of pyridine and heated at 100 ° C for 5 hours. After concentration, it is recrystallized from ethyl acetate. Get Z-acetyl-5-3,4-dimethoxyphenyl-2-oxazolidinone. Output 73%, Tr, l .. 175-182 ° C.
    Example B. 5- (3,4-Dimethoxyphenyl) -5-propyl-2-oxazolidinone.
    56 mmol of 3,4-dimethoxybutyrophenone and 61.4 mmol of trimethylacyl cinidide with an addition of 200 mg {627 mmol) of anhydrous zinc iodide are heated at 90 ° C for 4 hours under nitrogen and in the absence of moisture. The reaction mixture is dissolved in 15 m of absolute tetrahydrofuran, and a suspension of 60 mmol of lithium aluminum hydride is added dropwise to the solution .. 35 ml of absolute tetrahydrofuran are heated at 60 ° C for 1 h under nitrogen atmosphere and excess lithium aluminum hydride is decomposed by adding acetic ether to a solution of acetic ether and a mixture of lithium aluminum hydroxide The precipitate is filtered off with suction, washed well with ethanol and the mother liquor is concentrated.
    CicTaTOK is dissolved in acetic acid ester, acidified with 4 g of hydrochloric acid and shaken. The aqueous phase is adjusted to pH 9 with sodium carbonate, saturated with sodium chloride and extracted with chloroform. The chloroform phase is washed daily with a saturated solution of sodium chloride and the solvent is distilled off after drying over sodium sulfate. 5-amino-4 (3,4-dimethoxyphenyl) -4-pentanol is obtained in the form of an oil, yield 75.5%. The analyzed sample as hydrochloride melts at 175-176 ° C.
    17.35 mmol of 5-amino-4- (3,4-dimethoxyphenyl) -4-pentanol dissolved in 10 ml of absolute dimethylformamide, 18.3 mmol of 98% carbonyldiimidazole in 100 ml of absolute tetrahydrofuran were added and left for four days at room temperature and in the absence of moisture. After distilling off the solvent, the residue is dissolved in ethyl acetate, shaken twice with 1N hydrochloric acid and washed until neutral with a saturated solution of sodium chloride. The resulting oil is purified on a column of silica gel (350 g) in the chloroform / methanol system (30; 1). 5- (3,4-dimethoxyphenyl) -5-propyl-2-oxazolidinone is obtained as an oil. Yield 81.7%.
    Example 9 , 5- (3, 4-21 dimethoxyphenyl) -5-methyl-2-oxazolidinone.
    Analogously to example 8, from 3,4-dimethoxy-acetophenone, 5- (3,4-dimethoxyphenyl) -5-methyl-2-oxazolidinone is obtained with a total yield of 30% and Trd, 98-101 ° C.
    Example 10. 5- (3,4-Dimethoxyphenyl) -4-methyl-2-oxazolidinone.
    5.5 mmol 2-amino-1- (3,4-dimethoxyphenyl) propanol is dissolved in 50 ml of chloroform and together with 1.05 g (6.5 mmol) of carbonyldiimidazole is stirred for 2 hours in the absence of moisture. After standing overnight, it is extracted with 50 ml of distilled water, dried, filtered and concentrated. Then the residue is chromatographed on 50 g of silica gel using chloroform / methanol (95: 5) as an aluminizing agent and recrystallized from ethyl acetate / petroleum ether. 5 .- (3,4-dimethoxyphenyl) -4-methyl-2-oxazolidinone is obtained. yield 24%. . 98-99 ° C.
    The starting compound 2-amino-1- (3,4-dimethoxyphenyl) propanol was prepared as follows.
    To 100 mmol 3,4-dimetic Jnopropiophenone in 160 ml of methylene chloride are added dropwise at room temperature 10 ml of sulfuryl chloride in 80 ml of methylene chloride and stirred for 3.5 hours at room temperature. After removal, it is dissolved and recrystallized from the mixture of cyclohexane and petroleum ether, 2-chloro-3, 4-dimethoxypropiophenone is obtained. Yield 89%, mp. 56-57 ° C.
    43.86 mmol of 2-chloro-3,4-dimethoxypropiophenone, dissolved in 230 m of acetone, together with 437 mg of potassium iodide and 87.72 mmol of dibenzylamine are stirred in the absence of moisture for 7 days. The mixture is diluted to obtain a solution of 1 liter of diethyl ether, filtered and concentrated. The residue is taken up with silica gel, which is stirred first with chloroform and then with ethanol IF, if necessary, aspirated. The chloroform phase is chromatographed on 500 g of silica gel with chloroform as a solvent; N-dibenzylamino-3,4-dimethoxypropiophenone is obtained as an oil. Yield 49%.
    12.39 g (31.8 mmol) of 2-K, N-dibenzylamino-3, 4-dimethoxypropiophenone is dissolved in 75 ml of isopropanol and mixed with 1.33 g (35.05 mmol) of sodium borane. After stirring for 1 hour at room temperature, the mixture is heated to reflux for 2 hours. The mixture is then cooled, sucked off and the residue is boiled with ethyl acetate. After filtration, 2 - (H, H-dibenzylamino) -1- (3,4-dimethoxyphenyl) propanol is crystallized from the filtrate. Yield 59%, TPD. 151-152s.
    13.2 mmol of dibenele compound in 50 ml of ethanol is hydrogenated with 2.64 g of palladium on coal (10%) for 3 hours at 90 ° C and a hydrogen pressure of 10 ppm. After suctioning, the mixture is concentrated and recrystallized by ethanol. 2-amino-i- (3,4-dimethoxyphenyl) propanol is obtained. Yield 64%, TPA, 131-132C.
    权利要求:
    Claims (1)
    [1]
    1. Patent of England 1386613, clg C 07 D 263/20, 1975.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU888821A3|1981-12-07|Method of preparing 5-|-oxazolidinones or their sulphur-containing analogs
    FR2561647A1|1985-09-27|1- | -1,6,7,11B-TETRAHYDRO-2H, 4H- | -OXAZINO- OR -THIAZINO | ISOQUINOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING
    Baudy et al.1978|Reaction of N-substituted thioamides with gem-dicyano epoxides: a new synthetic route to anhydro-4-hydroxythiazolium hydroxides
    FI81339C|1990-10-10|FOERFARANDE FOER FRAMSTAELLNING AV PYRROLIDINODERIVAT, MELLANPRODUKT OCH DESS FRAMSTAELLNINGSFOERFARANDE.
    US4046778A|1977-09-06|Processes for the preparation of 4-hydroxy-2H-1-benzothiopyran-3-carboxamide 1,1-dioxides
    US4007203A|1977-02-08|4-|-2H-1-benzothiopyran-3-carboxanilide
    SU950188A3|1982-08-07|Process for producing derivatives of 4|-mercaptomethylimidazoles
    JPH07116126B2|1995-12-13|2,3-diaminoacrylonitrile derivative
    Chupp et al.1980|Heterocycles from substituted amides. VII Oxazoles from 2‐isocyanoacetamides
    FR2481280A1|1981-10-30|PROCESS FOR THE PREPARATION OF 2-GUANIDINOTHIAZOLE DERIVATIVES, NOVEL PRODUCTS THUS OBTAINED AND THEIR USE AS AGENTS AGAINST STOMACH ULCERS
    SU900802A3|1982-01-23|Process for preparing ethyleleiminocyanoazomethines
    CS203026B2|1981-02-27|Process for preparing new derivatives of arylaminoimidazoline
    FR2618779A1|1989-02-03|NEW PROCESS FOR THE PREPARATION OF 1,2,4-TRIAZOL-3-ONES
    US4477677A|1984-10-16|Process for the preparation of 1-|-5-methoxy-2-methyl-3-indoleacetoxyacetic acid
    US3251855A|1966-05-17|Derivatives of phthalimide
    JP2579532B2|1997-02-05|Aminoacetonitrile derivative and method for producing the same
    US4290971A|1981-09-22|Method of preparing 2-|-imidazolines-|
    US5162534A|1992-11-10|Process for the preparation of thiazoline derivatives
    JP2578797B2|1997-02-05|Method for producing N- | formamides
    KR920009884B1|1992-11-05|2,3-thiomorpholinedione-2-oxime derivatives and process for preparing same
    US5705651A|1998-01-06|Process for producing a 3,4-alkylene-1,3,4-thiadiazolidin-2-one and intermediates for the same
    CA2039114A1|1991-09-28|4h-pyrrolo[1,2-a]thieno[2,3-f]diazepine[1,4]derivatives, a process for their preparation and pharmaceutical compositions holding same
    US4013686A|1977-03-22|4-|-2h-1-benzothiopyran-1,1-dioxide
    US4459415A|1984-07-10|Process for the preparation of 1-|-5-methoxy-2-methyl-3-indoleacetoxyacetic acid
    KR920005828B1|1992-07-20|Process for preparing salt of 2-|-thiomethyl-5-dimethyl amino methylfuran
    同族专利:
    公开号 | 公开日
    IE772446L|1978-06-03|
    NL7713153A|1978-06-06|
    DK149850B|1986-10-13|
    IT1089341B|1985-06-18|
    IE46435B1|1983-06-15|
    CS199694B2|1980-07-31|
    FR2372814B1|1980-10-10|
    IL53520D0|1978-03-10|
    JPS6154792B2|1986-11-25|
    DD133667A5|1979-01-17|
    AT357529B|1980-07-10|
    SE441446B|1985-10-07|
    AU3117577A|1979-06-07|
    FR2372814A1|1978-06-30|
    CA1097657A|1981-03-17|
    SE7713635L|1978-06-04|
    GB1588639A|1981-04-29|
    LU78616A1|1978-04-20|
    JPS5382777A|1978-07-21|
    HU175676B|1980-09-28|
    ATA868677A|1979-12-15|
    GR64964B|1980-06-10|
    AU519994B2|1982-01-07|
    DK149850C|1987-04-27|
    IL53520A|1981-07-31|
    CH635578A5|1983-04-15|
    DK536677A|1978-06-04|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    DE2701215C2|1977-01-13|1982-10-14|Bayer Ag, 5090 Leverkusen|Process for the preparation of thiazoline-2-thiones|
    US4348393A|1978-06-09|1982-09-07|Delalande S.A.|N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones|
    DE3438839A1|1984-10-19|1986-04-24|Schering AG, 1000 Berlin und 4709 Bergkamen|PHARMACEUTICAL PREPARATIONS|
    HU215433B|1986-04-29|2000-05-28|Pfizer Inc.|Process for producing new 2-oxo-5-phenyl-pyrimidin derivatives|
    US5459145A|1988-01-19|1995-10-17|Pfizer Inc.|Calcium independent camp phosphodiesterase inhibitor antidepressant|
    JPH01135098U|1988-03-11|1989-09-14|
    WO1991007177A1|1989-11-13|1991-05-30|Pfizer Inc.|Pyrimidone derivatives and analogs in the treatment of asthma or certain skin disorders|
    US5461056A|1992-05-08|1995-10-24|Pfizer Inc.|Pyrimidone derivatives and analogs in the treatment of asthma or certain skin disorders|
    GB9212673D0|1992-06-15|1992-07-29|Celltech Ltd|Chemical compounds|
    GB9222253D0|1992-10-23|1992-12-09|Celltech Ltd|Chemical compounds|
    US5622977A|1992-12-23|1997-04-22|Celltech Therapeutics Limited|Tri-substitutedderivatives and pharmaceutical compositions containing the same|
    GB9226830D0|1992-12-23|1993-02-17|Celltech Ltd|Chemical compounds|
    GB9304919D0|1993-03-10|1993-04-28|Celltech Ltd|Chemical compounds|
    GB9304920D0|1993-03-10|1993-04-28|Celltech Ltd|Chemical compounds|
    WO1995017399A1|1993-12-22|1995-06-29|Celltech Therapeutics Limited|Trisubstituted phenyl derivatives, processes for their preparation and their use as phosphodiesteraseinhibitors|
    GB9326173D0|1993-12-22|1994-02-23|Celltech Ltd|Chemical compounds and process|
    US5786354A|1994-06-21|1998-07-28|Celltech Therapeutics, Limited|Tri-substituted phenyl derivatives and processes for their preparation|
    US6245774B1|1994-06-21|2001-06-12|Celltech Therapeutics Limited|Tri-substituted phenyl or pyridine derivatives|
    GB9412573D0|1994-06-22|1994-08-10|Celltech Ltd|Chemical compounds|
    GB9412571D0|1994-06-22|1994-08-10|Celltech Ltd|Chemical compounds|
    GB9412672D0|1994-06-23|1994-08-10|Celltech Ltd|Chemical compounds|
    GB9523675D0|1995-11-20|1996-01-24|Celltech Therapeutics Ltd|Chemical compounds|
    GB9526246D0|1995-12-21|1996-02-21|Celltech Therapeutics Ltd|Chemical compounds|
    GB9526245D0|1995-12-21|1996-02-21|Celltech Therapeutics Ltd|Chemical compounds|
    GB9608435D0|1996-04-24|1996-06-26|Celltech Therapeutics Ltd|Chemical compounds|
    GB9619284D0|1996-09-16|1996-10-30|Celltech Therapeutics Ltd|Chemical compounds|
    GB9622363D0|1996-10-28|1997-01-08|Celltech Therapeutics Ltd|Chemical compounds|
    GB9625184D0|1996-12-04|1997-01-22|Celltech Therapeutics Ltd|Chemical compounds|
    US6057329A|1996-12-23|2000-05-02|Celltech Therapeutics Limited|Fused polycyclic 2-aminopyrimidine derivatives|
    GB9705361D0|1997-03-14|1997-04-30|Celltech Therapeutics Ltd|Chemical compounds|
    GB9713087D0|1997-06-20|1997-08-27|Celltech Therapeutics Ltd|Chemical compounds|
    GB9914258D0|1999-06-18|1999-08-18|Celltech Therapeutics Ltd|Chemical compounds|
    GB9924862D0|1999-10-20|1999-12-22|Celltech Therapeutics Ltd|Chemical compounds|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    DE19762655369|DE2655369A1|1976-12-03|1976-12-03|5--OXAZOLIDINONE AND THEIR SULFUR ANALOGS AND PROCESS FOR THEIR PRODUCTION|
    DE19772745320|DE2745320A1|1977-10-05|1977-10-05|5-Alkoxyphenyl-oxazolidine-2-one and sulphur analogues - useful as neuroleptics and phospho-di:esterase inhibitors|
    [返回顶部]